FDA approves first treatment for rare blood disease - FDA Press Releases

The FDA approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.

from Food and Drug Administration--Press Releases http://bit.ly/2UZUDm8
via IFTTT